Molecularly targeted therapy: have the floodgates opened?
Druker
Brian J
BJ
Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA. drukerb@ohsu.edu
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D000068877:Imatinib Mesylate; D008495:Medical Oncology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate